Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss)
(U.S. Dollars in thousands, except per share amounts)
(Unaudited)
Three Months Ended Six Months Ended
September 30, September 30,
------------------------------ -----------------------
2024 2023 2024 2023
---------------- ------------ -------- -------------
Expenses
Research and
development $ 723 $ 4,237 $ 2,028 $ 7,865
General and
administrative
expenses 881 1,693 2,415 3,062
-------------- ------ --- ------ ------- ---
Loss from
operations (1,604) (5,930) (4,443) (10,927)
Change in fair
value of
warrant
liability (716) -- 426 --
Change in fair
value of
deferred
purchase price
payable --
Tarus and
deferred
obligation --
iOx milestone -- (113 ) -- (1,224 )
Gain on
settlement with
Parexel -- iOx
CRO 946 -- 946 --
Share of loss in
associate
accounted for
using equity
method -- (40) -- (90)
Depreciation
expense (7) (15) (15) (26)
Foreign exchange
transaction
(loss) gain (5) (17) (7) 1
Interest income,
net 24 43 69 123
-------------- ------ --- ------ ------- ---
Loss before
benefit for
income taxes (1,362) (6,072) (3,024) (12,143)
Income tax
benefit
(expense) -- 907 (2) 1,052
-------------- ------ --- ------ ------- ---
Net loss (1,362) (5,165) (3,026) (11,091)
Other
comprehensive
income (loss)
Net unrealized
(loss) gain on
investments -- (1,300) -- 469
-------------- ------ ------ ------- ---
Total
comprehensive
loss for period $ (1,362) $(6,465) $(3,026) $(10,622)
============== ====== ====== =======
Net loss
attributable to:
Owners of the
Company $ (1,360) $(5,158) $(3,016) $(11,077)
Non-controlling
interest (2) (7) (10) (14)
-------------- ------ ------ -------
Net loss $ (1,362) $(5,165) $(3,026) $(11,091)
============== ====== ====== =======
Comprehensive loss
attributable to:
Owners of the
Company $ (1,360) $(6,458) $(3,016) $(10,608)
Non-controlling
interest (2) (7) (10) (14)
-------------- ------ ------ -------
Total
comprehensive
loss for period $ (1,362) $(6,465) $(3,026) $(10,622)
Loss per share
Basic and
diluted $ (1.26) $ (5.80) $ (2.84) $ (12.47)
============== ====== ====== =======
Weighted average
shares
outstanding
Basic and
diluted 1,076 890 1,063 888
============== ====== === ====== ======= ===
PORTAGE BIOTECH INC.
Condensed Consolidated Interim Statements of Financial Position
(U.S. Dollars in thousands)
(Unaudited)
September 30, March 31,
2024 2024
--------------- ------------
(Audited)
Assets
Current assets
Cash and cash equivalents $ 1,764 $ 5,028
Prepaid expenses and other current
assets 922 2,667
----------- --------
Total current assets 2,686 7,695
----------- --------
Non-current assets
Right to use asset 20 35
Other assets -- 49
----------- --------
Total non-current assets 20 84
----------- --------
Total assets $ 2,706 $ 7,779
=========== ========
Liabilities and Equity
Current liabilities
Accounts payable and accrued liabilities $ 845 $ 2,836
Lease liability - current, including
interest 28 40
Other current liabilities -- 3
----------- --------
Total current liabilities 873 2,879
----------- --------
Non-current liabilities
Lease liability - non-current -- 7
Warrant liability 1,138 1,564
----------- --------
Total non-current liabilities 1,138 1,571
----------- --------
Total liabilities 2,011 4,450
----------- --------
Shareholders' Equity
Capital stock 219,606 219,499
Stock option reserve 24,126 23,841
Accumulated deficit (242,334) (239,318)
----------- --------
Total equity attributable to owners of the
Company 1,398 4,022
Non-controlling interest (703) (693)
----------- --------
Total equity 695 3,329
----------- --------
Total liabilities and equity $ 2,706 $ 7,779
=========== ========
(END) Dow Jones Newswires
November 26, 2024 16:05 ET (21:05 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.